Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects
Efficacy of Nitraria Retusa Infusion in Significantly Reducing Clozapine-induced Metabolic Side Effects in Patients With Treatment-resistant Schizophrenia: A Pre-Experimental Pilot Study
The primary objective of the study is to assess the efficacy and tolerability of a 90-day daily supplementation with a Nitraria retusa dried crushed leaves infusion on the iatrogenic metabolic side effects induced in patients with treatment-resistant schizophrenia following clozapine treatment.
After providing written informed consent, eligible patients with treatment-resistant schizophrenia will be invited to receive a daily Nitraria retusa extract infusion at approximately 9 PM for 90 consecutive days, as an adjunct to their usual medications. Patients will be instructed to maintain their usual diet, routine, and lifestyle throughout the study.
Clinical and biological evaluations will be conducted prospectively at baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3). Two additional assessments will be planned at day 30 and day 60 to comply with the monthly complete blood count (CBC) surveillance recommended for patients receiving clozapine. Assessments include anthropometric measures, body composition, vital signs, CBC, metabolic panels, and renal and hepatic function. All biological samples were collected after a 12-hour fast.
研究概览
详细说明
A pilot, pre-experimental study will be conducted.
- Study population Patients will be recruited from the outpatient Department of Psychiatry at Farhat Hached Hospital (Sousse, Tunisia). Inclusion criteria are: (1) a diagnosis of treatment-resistant schizophrenia; (2) current treatment with clozapine monotherapy or clozapine combined with other psychotropics that have a minimal documented impact on body weight; (3) demonstration of a response to clozapine, defined as a reduction of at least 20% in the total score on the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) after 8-12 weeks of treatment at effective therapeutic doses; and (4) presence of obesity (Body Mass Index (BMI) > 30 kg/m²) or central obesity (waist circumference > 94 cm in men and > 80 cm in women), which developed following clozapine introduction. Non-inclusion criteria are: (1) concurrent use of clozapine with other psychotropic agents that have a documented moderate-to-high influence on body weight; (2) current treatment with metformin; and (3) pregnancy or breastfeeding.
- Study procedure Eligible patients with treatment-resistant schizophrenia will be invited to take a daily Nitraria retusa extract infusion at approximately 9 PM for 90 consecutive days, as an adjunct to their usual medications. Patients will be instructed to maintain their usual diet, routine, and lifestyle throughout the study. Clinical and biological evaluations will be conducted prospectively at baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3).
- Plant material and preparation of Nitraria retusa extract Nitraria retusa was collected from saline soils in Kairouan (central Tunisia). The leaves were rinsed with water, air-dried in the shade at room temperature for 15 days, and crushed into a fine powder using a Moulinex grinder (MOULINEX SA, France). Nitraria retusa was supplied to participants in sachets containing 2,000 mg of powder. Participants were instructed to prepare the daily infusion by steeping 2,000 mg of the powder in 100 mL of boiled water for 15 minutes. Qualitative and quantitative analyses of the extract were performed using a validated ultra-high-performance liquid chromatography with diode-array detection method (UHPLC-DAD; SHIMADZU 8045).
Outcome variables Outcome measures were categorized as primary and secondary.
Primary outcomes included:
- Body weight, measured using a calibrated scale integrated into the bioelectrical impedance analyzer, with participants wearing light clothing.
- Waist circumference, measured at the narrowest point between the lower rib margin and the iliac crest, as an indicator of abdominal adiposity.
Secondary outcomes encompassed:
- Other anthropometric measurements including mid-upper arm circumference measured at the midpoint of the relaxed arm, and mid-thigh circumference measured at the midpoint of the thigh.
- Body composition, assessed via bioelectrical impedance analysis, including body fat, muscle mass, and body water percentages.
- Metabolic panels, including triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose, and glycated hemoglobin (HbA1c).
- Intervention tolerability, monitored via CBC, renal function markers, and hepatic enzymes.
- Ethical considerations Each participant provided written informed consent after receiving a detailed oral explanation of the study objectives and procedure, and after being given the written information sheet. Participants were also informed about their rights to withdraw at any time without any impact on the quality of their clinical care. All data were handled confidentially.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Bochra Nourhène Saguem, M.D.; Associate Professor
- 电话号码:+21655617728
- 邮箱:saguem.bochra@gmail.com
研究联系人备份
- 姓名:Saad Saguem, Professor
- 电话号码:+21653673851
- 邮箱:khaled_saguem@yahoo.fr
学习地点
-
-
-
Sousse、突尼斯、4000
- 招聘中
- Farhat Hached University Hospital
-
接触:
- Bochra Nourhène Saguem, M.D.; Associate Professor
- 电话号码:+21655617728
- 邮箱:saguem.bochra@gmail.com
-
副研究员:
- Jaâfar Nakhli, Professor
-
首席研究员:
- Bochra Nourhène Saguem, M.D.; Associate Professor
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- a diagnosis of treatment-resistant schizophrenia;
- current treatment with clozapine monotherapy or clozapine combined with other psychotropics that have a minimal documented impact on body weight; - demonstration of a response to clozapine, defined as a reduction of at least 20% in the total score on the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) after 8-12 weeks of treatment at effective therapeutic doses;
- presence of obesity (BMI > 30 kg/m²) or central obesity (waist circumference > 94 cm in men and > 80 cm in women), which developed following clozapine introduction.
- free informed written consent
Exclusion Criteria:
- concurrent use of clozapine with other psychotropic agents that have a documented moderate-to-high influence on body weight
- current treatment with metformin
- pregnancy or breastfeeding
- non acceptance to take part to the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment-resistant schizophrenia patients' with clozapine-induced obesity
Inclusion criteria: (1) a diagnosis of treatment-resistant schizophrenia]; (2) current treatment with clozapine monotherapy or clozapine combined with other psychotropics that have a minimal documented impact on body weight; (3) demonstration of a response to clozapine, defined as a reduction of at least 20% in the total score on the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) after 8-12 weeks of treatment at effective therapeutic doses; and (4) presence of obesity (BMI > 30 kg/m²) or central obesity (waist circumference > 94 cm in men and > 80 cm in women), which developed following clozapine introduction. Non-inclusion criteria: (1) concurrent use of clozapine with other psychotropic agents that have a documented moderate-to-high influence on body weight; (2) current treatment with metformin; and (3) pregnancy or breastfeeding. |
A daily administration of Nitraria retusa extract infusion at approximately 9 PM for 90 consecutive days, as an adjunct to patients' usual medications, while maintaining usual diet, routine, and lifestyle throughout the study. Nitraria retusa was collected from saline soils in Kairouan (central Tunisia). The leaves were rinsed with water, air-dried in the shade at room temperature for 15 days, and crushed into a fine powder using a Moulinex grinder (MOULINEX SA, France). Nitraria retusa was supplied to participants in sachets containing 2,000 mg of powder. Participants were instructed to prepare the daily infusion by steeping 2,000 mg of the powder in 100 mL of boiled water for 15 minutes. Qualitative and quantitative analyses of the extract were performed using a validated high-performance liquid chromatography method (UHPLC-DAD, SHIMADZU 8045). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Body weight
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Body weight, measured using a calibrated scale integrated into the bioelectrical impedance analyzer, with participants wearing light clothing.
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Waist circumference
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Waist circumference, measured at the narrowest point between the lower rib margin and the iliac crest, as an indicator of abdominal adiposity.
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Other anthropometric measurements
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Other anthropometric measurements including mid-upper arm circumference measured at the midpoint of the relaxed arm, and mid-thigh circumference measured at the midpoint of the thigh.
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Body composition
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Body composition, assessed via bioelectrical impedance analysis, including body fat percentage, muscle mass percentage, and body water percentage.
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Concentration of Triglycerides
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Fasting serum triglyceride (TG) concentration
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Concentration of High-Density Lipoprotein Cholesterol
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Fasting serum High-Density Lipoprotein Cholesterol (HDL-C) concentration
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Concentration of Low-Density Lipoprotein Cholesterol
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Fasting serum Low-Density Lipoprotein Cholesterol (LDL-C) concentration
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Fasting Blood Glucose Level
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Fasting plasma glucose concentration
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
|
Glycated Hemoglobin (HbA1c) Level
大体时间:baseline (T0) and day 90 (T3)
|
Percentage of glycated hemoglobin (HbA1c)
|
baseline (T0) and day 90 (T3)
|
|
Incidence of treatment-emergent abnormalities in Complete Blood Count, renal function, and hepatic Enzymes
大体时间:baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
Number of participants with clinically significant treatment-emergent abnormalities in complete blood count (CBC), renal function markers, or hepatic enzymes during the 90-day intervention period.
|
baseline (T0), day 10 (T1), day 45 (T2), and day 90 (T3)
|
合作者和调查者
调查人员
- 研究主任:Saad Saguem, Professor、Faculty of Medicine, Sousse
出版物和有用的链接
一般刊物
- Yao J, Zhang Y, Zhao J, Wang XZ, Lin YP, Sun L, Lu QY, Fan GJ. Efficacy of flavonoids-containing supplements on insulin resistance and associated metabolic risk factors in overweight and obese subjects: a systematic review and meta-analysis of 25 randomized controlled trials. Front Endocrinol (Lausanne). 2022 Jul 22;13:917692. doi: 10.3389/fendo.2022.917692. eCollection 2022.
- Laouani A, Nasrallah H, Sassi A, Ferdousi F, Kalai FZ, Hasni Y, Limem K, Isoda H, Saguem S. Exploring the Effects of Short-Term Daily Intake of Nitraria retusa Tea on Lipid Profile: A Pre-Post, Uncontrolled Pilot Study in Both Healthy and Overweight/Obese Adults. Nutrients. 2023 Aug 20;15(16):3649. doi: 10.3390/nu15163649.
- Laouani A, Nasrallah H, Sassi A, Ferdousi F, Kalai FZ, Hasni Y, Isoda H, Saguem S. Antiobesity and Hypolipidemic Potential of Nitraria retusa Extract in Overweight/Obese Women: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients. 2024 Jan 21;16(2):317. doi: 10.3390/nu16020317.
- Yuen JWY, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM. A Focused Review of the Metabolic Side-Effects of Clozapine. Front Endocrinol (Lausanne). 2021 Feb 25;12:609240. doi: 10.3389/fendo.2021.609240. eCollection 2021.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CEFMS 136/2022
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享支持信息类型
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.